Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Nodal Peripheral T-Cell Lymphoma of T Follicular Helper Cell Origin”

4 trials

Showing 4 of 4 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT02223208
What this trial is testing

Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas

Who this might be right for
Peripheral T-cell Lymphomas (PTCL)PTCL-NOSAngioimmunoblastic T-cell Lymphoma (AITL)+2 more
Fondazione Italiana Linfomi - ETS 89
Testing effectiveness (Phase 2)Ended earlyNCT04251065
What this trial is testing

Daratumumab Plus Gemcitabine, Dexamethasone, Cisplatin in pt R/R CD38+ PTCL-NOS, AITL and TFH

Who this might be right for
Refractory T-Cell LymphomaRelapsed T-Cell Lymphoma
Fondazione Italiana Linfomi - ETS 8
Testing effectiveness (Phase 2)Ended earlyNCT03552692
What this trial is testing

Use of Venetoclax as Single Agent in Patients With Relapsed/Refractory BCL-2 Positive Peripheral T Cell Lymphoma

Who this might be right for
T-Cell Lymphoma RelapsedT-Cell Lymphoma Refractory
Fondazione Italiana Linfomi - ETS 22
Testing effectiveness (Phase 2)Active Not RecruitingNCT06035497
What this trial is testing

Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)

Who this might be right for
Relapsed or Refractory T-cell Lymphomas
Bristol-Myers Squibb 85

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation